Cetuximab in advanced non-small cell lung cancer

Critical Reviews in Oncology/Hematology

Volumn 59, Issue 2, 2006, Pages 139-149

  Rossi, Antonio ^a   Maione, Paolo ^a   Gridelli, Cesare ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

Cetuximab; NSCLC

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; MATUZUMAB; MONOCLONAL ANTIBODY; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PELITINIB; PEMETREXED; PERTUZUMAB;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACNE; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHIMERA; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; DRY SKIN; DYSPNEA; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; HEAD AND NECK CARCINOMA; HUMAN; IN VITRO STUDY; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALAISE; MYALGIA; NAUSEA; NEUROPATHY; PROTEIN DOMAIN; PROTEIN FAMILY; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; SKIN DISEASE; SKIN MANIFESTATION; SKIN TOXICITY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; EPIDERMAL GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 33746205322     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.02.006     Document Type: Review

References (87)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: globocan. Int J Cancer 94 (2001) 153-156
2. Coleman M.P., Gatta G., Verdecchia A., et al. EUROCARE-3 summary: cancer survival in Europe at the end of 20th century. Ann Oncol 14 Suppl. 5 (2003) 128-149
3. Borras J.M., Fernandez E., Gonzalez J.R., et al. Lung cancer mortality in European regions. Ann Oncol 14 (2003) 159-161
4. Tyczynski J.E., Bray F., and Parkin D.M. Lung cancer in Europe in 2000: epidemiology, prevention, and early detection. Lancet Oncol 4 (2003) 45-55
5. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., and Thun M.J. Cancer statistics, 2003. CA Cancer J Clin 53 (2003) 5-26
6. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311 (1995) 899-909
7. Salomon D.S., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Haematol 19 (1995) 183-232
8. Rusch V., Mendelsohn J., and Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev 7 (1996) 133-141
9. Raby B., Pater J., and Mackillop W. Does knowledge guide practice? Another look at the management of non-small-cell lung cancer. J Clin Oncol 13 (1995) 1904-1911
10. Chemotherapy for non-small cell lung cancer: Non-small Cell Lung Cancer Collaborative Group. Cochrane Database of Systematic Reviews 2000; CD002139.
11. Cullen M.H., Billingham L.J., Woodroffe C.M., et al. Mitomycin, ifosfamide and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17 (1999) 3188-3194
12. Thongprasert S., Sanguanmitra P., Juthapan W., and Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 24 (1999) 17-24
13. Spiro S.G., Rudd R.M., Souhami R.L., et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 59 (2004) 828-836
14. Crino L., Scagliotti G.V., Ricci S., et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17 (1999) 3522-3530
15. Gebbia V., Galetta D., Riccardi R., et al. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study. Lung Cancer 37 (2002) 179-187
16. Giaccone G., Splinter T.A., Debruyne C., et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer: The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 16 (1998) 2133-2141
17. Alberola V., Camps C., Provencio M., et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 21 (2003) 3207-3213
18. Le Chevalier T., Brisgand D., Douillard J.Y., et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of European Multicenter trial including 612 patients. J Clin Oncol 12 (1994) 360-367
19. Cardenal F., Lopez-Cabrerizo M.P., Anton A., et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17 (1999) 12-18
20. Bonomi P., Kim K., Fairclough D., et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18 (2000) 623-631
21. Hotta K., Matsuo K., Ueoka H., Kiura K., Tabata M., and Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 22 (2004) 3852-3859
22. Chan A.M., Mao A.J., Wu T., et al. Meta-analysis comparing carboplatin and cisplatin-based chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 23 16S (2005) 674s [abstract 7218]
23. Pfister D.G., Johnson D.H., Azzoli C.G., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update. J Clin Oncol 22 (2004) 330-353
24. Georgoulias V., Papadakis E., Alexopoulos A., et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357 (2001) 1478-1484
25. Smit E.F., van Meerbeeck J.P., Lianes P., et al. Three-arm randomised study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell by cancer: a phase III trial of European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21 (2003) 3909-3917
26. Gridelli C., Gallo C., Shepherd F.A., et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemtocitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21 (2003) 3025-3034
27. Gridelli C., Ardizzoni A., Le Chevalier T., et al. Treatment of advanced non small cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 15 (2004) 419-426
28. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review 1975-2000. Bethesda, MD, National Cancer Institute, 2003. http://seer.cancer.gov/csr/1975_2000 (accessed on June 30th, 2005).
29. Gridelli C., Perrone F., and Monfardini S. Lung cancer in the elderly. Eur J Cancer 33 (1997) 2313-2314
30. Gridelli C., Maione P., Rossi A., Di Maio M., and Perrone F. Chemotherapy of stage I to III non-small cell lung cancer in the elderly patients. Proceedings of the 41st annual meeting of American Society of Clinical Oncology, educational book. Orlando, FL, 13-17 May (2005) 611-617
31. Gridelli C., Perrone F., Gallo C., et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95 (2003) 362-372
32. Lewis J.H., Kilgore M.L., Goldman D.P., et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21 (2003) 1383-1389
33. Hutchins L.F., Unger J.M., Crowley J.J., Coltman Jr. C.A., and Albain K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341 (1999) 2061-2067
34. Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91 (1999) 66-72
35. Gridelli C., Aapro M., Ardizzoni A., et al. Treatment of advanced non small cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 23 (2005) 3125-3137
36. Ullrich A., and Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 61 (1990) 203-212
37. Normanno N., Bianco C., De Luca A., Maiello M.R., and Salomon D.S. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 10 (2003) 1-21
38. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 (2001) 127-137
39. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20 Suppl. 18 (2002) 1S-13S
40. Kurie J.M., Shin H.J., Lee J.S., et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 2 (1996) 1787-1793
41. Ciardiello F., and Tortora G. Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Invest Drugs 11 (2002) 755-768
42. Mendelsohn J., and Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21 (2003) 2787-2799
43. Grunwald V., and Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95 (2003) 851-867
44. Langer C.J. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int J Radiat Oncol Biol Phys 58 (2004) 991-1002
45. Herbst R.S., Kim E.S., and Harari P.M. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Expert Opin Biol Ther 1 (2001) 1-14
46. Humblet Y. Cetuximab: an IgG1 monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. Expert Opin Pharmacother 5 (2004) 1621-1633
47. Milas L., Mason K., Hunter N., et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6 (2000) 701-708
48. Kim E.S., Khuri F.R., and Herbst R.S. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 13 (2001) 506-513
49. Bruns C.J., Harbison M.T., Davis D.W., et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6 (2000) 1936-1948
50. Jung Y.D., Mansfield P.F., Akagi M., et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 38 (2002) 1133-1140
51. Prewett M.C., Hooper A.T., Bassi R., Ellis L.M., Waksal H.W., and Hicklin D.J. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8 (2002) 994-1003
52. Huang S.M., Armstrong E., Chinnaiyan P., and Harari P.M. Dual agent molecular targeting of epidermal growth factor receptor: combining anti-HER1/EGFR monoclonal antibody with tyrosine kinase inhibitor. Proc Am Assoc Cancer Res 44 (2003) 215 [abstract 3777]
53. Ye D., Mendelsohn J., and Fan Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 18 (1999) 731-738
54. Yamashita Y., Yamazaki M., Ohira M., et al. Anti-receptor signalling strategy in esophageal carcinoma: double targeting against egfr and her. Proc Am Assoc Cancer Res 45 (2004) 301 [abstract 5351]
55. Burtness B., Goldwasser M.A., Flood W., Mattar B., and Forastiere A.A. Phase III randomized trial of cisplatin plus placebo with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23 (2005) 8646-8654
56. Bonner J.A., Giralt J., Harari P.M., et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol 22 Suppl. 14 (2004) 489s [abstract 5507]
57. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
58. Lenz H.J., Mayer R.J., Gold P.J., et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc Am Soc Clin Oncol 23 (2004) 248 [abstract 3510]
59. Lenz H.J., Mayer R.J., Mirtsching B., et al. Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. J Clin Oncol 23 Suppl. 16 (2005) 255s [abstract 3536]
60. Spitzer G., Zackon I., Stella P., Zehngebot L., and Henderson C. Anti-epidermal growth factor antibody, cetuximab, in patients with stage IV colorectal carcinoma who failed all standard therapy: final report of an access protocol. J Clin Oncol 23 Suppl. 16 (2005) 282s [abstract 3646]
61. Rosenberg A.H., Loehrer P.J., Needle M.N., et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5-FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 21 (2002) 135a [abstract 536]
62. Rougier P., Raoul J.L., Van Laethem J.L., et al. Cetuximab + FOLFIRI as first-line treatment for metastatic colorectal CA. Proc Am Soc Clin Oncol 23 (2004) 248 [abstract 3513]
63. Diaz Rubio E., Tabernero J., van Cutsem E., et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study. J Clin Oncol 23 Suppl. 16 (2005) 254s [abstract 3535]
64. Polikoff J., Mitchell E.P., Badarinath S., et al. Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): preliminary efficacy analysis of a randomized phase III trial. J Clin Oncol 23 Suppl. 16 (2005) 264s [abstract 3574]
65. Scott J., Dakhil S., Cosgriff T., Pink C., Butler B., and Boccia R.V. Cetuximab + FOLFOX 6 as first line therapy for metastatic colorectal cancer. J Clin Oncol 23 Suppl. 16 (2005) 297s [abstract 3705]
66. Saltz L., Meropol N.J., Loehrer P.J., Needle M.N., Kopit J., and Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 (2004) 1201-1208
67. Busam K.J., Capodieci P., Motzer R., Kiehn T., Phelan D., and Halpem A.C. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144 (2001) 1169-1176
68. Saltz L., Kies M., Abbruzzese J.L., Azarnia N., and Needle M. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 22 (2003) 204 [abstract 817]
69. Baselga J., Pfister D., Cooper M.R., et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18 (2000) 904-914
70. Lilenbaum R., Bonomi P., Ansari R., et al. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC): final results. J Clin Oncol 23 Suppl. 16 (2005) 629s [abstract 7036]
71. Kim E.S., Mauer A.M., Tran H.T., et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report. Proc Am Soc Clin Oncol 22 (2003) 642 [abstract 2581]
72. Rosell R., Daniel C., Ramlau R., et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 23 (2004) 618 [abstract 7012]
73. Robert F., Blumenschein G., Herbst R.S., et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 9089-9096
74. Thienelt C.D., Bunn Jr. P.A., Hanna N., et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 23 (2005) 8786-8793
75. Blumenschein G., Swann S., Curran W., et al. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): an interim overall toxicity report of the RTOG 0324 trial. Lung Cancer 49 Suppl. 2 (2005) S78 [abstract PD-039]
76. PDQ National Cancer Institute Clinical Trials Database. Available at: http://www.cancer.gov/clinicaltrials. Accessed February 7th, 2006.
77. Silvestri G., Pritchard R., and Welch H.G. Preferences for chemotherapy in patients with advanced non-small-cell lung cancer: descriptive study based on scripted interviews. Br Med J 317 (1998) 771-775
78. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
79. Chung K.Y., Shia J., Kemeny N.E., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23 (2005) 1803-1810
80. Pippas A.W., Lenz H.J., Mayer R.J., et al. Analysis of EGFR status in metastatic colorectal cancer patients treated with cetuximab monotherapy. J Clin Oncol 23 Suppl. 16 (2005) 269s [abstract 3595]
81. Hirsch F.R., and Bunn P.A. Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?. J Clin Oncol 23 (2005) 9044-9047
82. Lynch T.J., Bell D.W., Sordella R., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. N Engl J Med 350 (2004) 2129-2139
83. Paez J.G., Jänne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
84. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101 (2004) 13306-13311
85. Huang S.F., Liu H.P., Li L.H., et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10 (2004) 8195-8203
86. Mukohara T., Engelman J.A., Hanna N.H., et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 97 (2005) 1185-1194
87. Moroni M., Veronese S., Benvenuti S., et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6 (2005) 279-286